Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer

Setsuko K Chambers, Joseph T. Chambers, Ernest I. Kohorn, Peter E. Schwartz

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Twenty-two patients with advanced epithelial ovarian cancer were treated with etoposide and cis-platinum. Each had failed one to three regimens of combination chemotherapy including cis-platinum-based combinations. Prior total cis-platinum doses ranged from 50 to 1600 mg/m2 with a median of 440 mg/m2. One of 18 evaluable patients had a complete response lasting 8 months, 1 had a partial response lasting 3 months, 8 had stable disease for a mean of 5.6 months, and 8 had progressive disease. The 4 unevaluable patients had undetectable clinical disease for a mean of 6.7 months. Bone marrow suppression was seen in 4 of 22 patients; two of whom had serious sequelae. The poor objective response rate (9.1%) seen with this combination in patients heavily pretreated with cis-platinum is similar to that seen for single agent etoposide in patients pretreated with alkylating agents. The difficulty of obtaining a good objective response in the face of prior cis-platinum-based combination chemotherapy failure is again verified.

Original languageEnglish (US)
Pages (from-to)233-240
Number of pages8
JournalGynecologic Oncology
Volume27
Issue number2
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Salvage Therapy
Etoposide
Cisplatin
Combination Drug Therapy
Alkylating Agents
Ovarian epithelial cancer
Bone Marrow

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer. / Chambers, Setsuko K; Chambers, Joseph T.; Kohorn, Ernest I.; Schwartz, Peter E.

In: Gynecologic Oncology, Vol. 27, No. 2, 1987, p. 233-240.

Research output: Contribution to journalArticle

Chambers, Setsuko K ; Chambers, Joseph T. ; Kohorn, Ernest I. ; Schwartz, Peter E. / Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer. In: Gynecologic Oncology. 1987 ; Vol. 27, No. 2. pp. 233-240.
@article{5d1e8ebf38524254962722bc45cf61aa,
title = "Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer",
abstract = "Twenty-two patients with advanced epithelial ovarian cancer were treated with etoposide and cis-platinum. Each had failed one to three regimens of combination chemotherapy including cis-platinum-based combinations. Prior total cis-platinum doses ranged from 50 to 1600 mg/m2 with a median of 440 mg/m2. One of 18 evaluable patients had a complete response lasting 8 months, 1 had a partial response lasting 3 months, 8 had stable disease for a mean of 5.6 months, and 8 had progressive disease. The 4 unevaluable patients had undetectable clinical disease for a mean of 6.7 months. Bone marrow suppression was seen in 4 of 22 patients; two of whom had serious sequelae. The poor objective response rate (9.1{\%}) seen with this combination in patients heavily pretreated with cis-platinum is similar to that seen for single agent etoposide in patients pretreated with alkylating agents. The difficulty of obtaining a good objective response in the face of prior cis-platinum-based combination chemotherapy failure is again verified.",
author = "Chambers, {Setsuko K} and Chambers, {Joseph T.} and Kohorn, {Ernest I.} and Schwartz, {Peter E.}",
year = "1987",
doi = "10.1016/0090-8258(87)90298-8",
language = "English (US)",
volume = "27",
pages = "233--240",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer

AU - Chambers, Setsuko K

AU - Chambers, Joseph T.

AU - Kohorn, Ernest I.

AU - Schwartz, Peter E.

PY - 1987

Y1 - 1987

N2 - Twenty-two patients with advanced epithelial ovarian cancer were treated with etoposide and cis-platinum. Each had failed one to three regimens of combination chemotherapy including cis-platinum-based combinations. Prior total cis-platinum doses ranged from 50 to 1600 mg/m2 with a median of 440 mg/m2. One of 18 evaluable patients had a complete response lasting 8 months, 1 had a partial response lasting 3 months, 8 had stable disease for a mean of 5.6 months, and 8 had progressive disease. The 4 unevaluable patients had undetectable clinical disease for a mean of 6.7 months. Bone marrow suppression was seen in 4 of 22 patients; two of whom had serious sequelae. The poor objective response rate (9.1%) seen with this combination in patients heavily pretreated with cis-platinum is similar to that seen for single agent etoposide in patients pretreated with alkylating agents. The difficulty of obtaining a good objective response in the face of prior cis-platinum-based combination chemotherapy failure is again verified.

AB - Twenty-two patients with advanced epithelial ovarian cancer were treated with etoposide and cis-platinum. Each had failed one to three regimens of combination chemotherapy including cis-platinum-based combinations. Prior total cis-platinum doses ranged from 50 to 1600 mg/m2 with a median of 440 mg/m2. One of 18 evaluable patients had a complete response lasting 8 months, 1 had a partial response lasting 3 months, 8 had stable disease for a mean of 5.6 months, and 8 had progressive disease. The 4 unevaluable patients had undetectable clinical disease for a mean of 6.7 months. Bone marrow suppression was seen in 4 of 22 patients; two of whom had serious sequelae. The poor objective response rate (9.1%) seen with this combination in patients heavily pretreated with cis-platinum is similar to that seen for single agent etoposide in patients pretreated with alkylating agents. The difficulty of obtaining a good objective response in the face of prior cis-platinum-based combination chemotherapy failure is again verified.

UR - http://www.scopus.com/inward/record.url?scp=0023263111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023263111&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(87)90298-8

DO - 10.1016/0090-8258(87)90298-8

M3 - Article

VL - 27

SP - 233

EP - 240

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -